Rate Notice: 5.9% general rate increase Jan 1, 2026 — Learn More
    Novo Nordisk pharmaceutical industry inc logo featuring a stylized blue and white Nordic cross design

    Novo Nordisk Pharm. Ind. Inc.

    Novo Nordisk Pharm. Ind. Inc. is a global leader in diabetes, obesity, and rare disease pharmaceuticals, driving innovation and patient care across the U.S. and worldwide.

    Company Overview

    Novo Nordisk Pharm. Ind. Inc. operates as part of Novo Nordisk, a leading international pharmaceutical company specializing in diabetes care, obesity management, and treatments for rare bleeding and growth hormone disorders. With a strong presence in the U.S., the company is recognized for pioneering scientific breakthroughs and expanding access to life-changing medicines. Their operations span research, development, manufacturing, and distribution of advanced therapies.

    Key Metrics

    1,200

    Import Shipments

    12

    Distribution Centers

    34.4B

    Annual Revenue

    1923

    Founded

    Company Profile

    Key Milestones

    Important company milestones and achievements.

    Markets Served

    Geographic markets and customer segments served.

    Ownership Structure

    Corporate ownership and organizational structure.

    Sales Channels

    Distribution networks and sales approaches.

    Recent Developments

    Novo Nordisk Pharm. Ind. Inc. is actively expanding its portfolio of diabetes and obesity treatments, responding to rising global demand and advancing research in chronic disease management.

    Strategic Expansion

    Launch of new obesity and diabetes drugs, including expanded indications for existing therapies

    Market Expansion

    Strategic efforts to expand market presence and reach new customer segments.

    Technology Adoption

    Implementation of advanced technologies to improve service delivery and customer experience.

    Business Information

    Novo Nordisk Pharm. Ind. Inc. is dedicated to defeating serious chronic diseases through innovative pharmaceutical solutions, focusing on diabetes, obesity, and rare disorders. The company manufactures and distributes a wide range of branded drugs, including injectable pens and hormone therapies, serving millions of patients. Their U.S. operations emphasize accessibility, quality, and long-term health outcomes, supported by robust research and development. Novo Nordisk’s commitment to patient-centered care and scientific excellence positions them as a trusted partner in global healthcare.

    Headquarters

    Bagsvaerd, Denmark (Global); U.S. operations based in Plainsboro, New Jersey

    Founded

    1923

    Stock Symbol

    NVO